Drug Trial Radar · NCT07571746
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
43
Planned (sponsor's estimate)
Start
Mar 28, 2026
Primary completion
Oct 13, 2028
Study completion Apr 15, 2030
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- May 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and efficacy of surovatamig administered by subcutaneous injection in adult participants with primary membranous nephropathy.
Conditions
- Primary Membranous Nephropathy
Interventions
SurovatamigDrug
Participants will receive Surovatamig subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events.Time frame: Through study completion, an average of 2 years
- Change from baseline in UPCR (from 24-hour urine collection or the intended 24-hour urine collection)Time frame: At 6 months
Locations
27 sites in 9 countries. Site status is shown where the registry gives one.
Research Site
Los Angeles, California · Withdrawn
Research Site
Los Angeles, California · Not yet recruiting
Research Site
Iowa City, Iowa · Not yet recruiting
Research Site
Bethesda, Maryland · Not yet recruiting
Research Site
New York, New York · Not yet recruiting
Research Site
Houston, Texas · Recruiting
Research Site
Houston, Texas · Not yet recruiting
Research Site
Ieper, Belgium · Not yet recruiting
Research Site
Beijing, China · Not yet recruiting
Research Site
Beijing, China · Not yet recruiting
Research Site
Bordeaux, France · Not yet recruiting
Research Site
Créteil, France · Withdrawn
Research Site
Lyon, France · Not yet recruiting
Research Site
Nantes, France · Not yet recruiting
Research Site
Nîmes, France · Not yet recruiting
Research Site
Düsseldorf, Germany · Not yet recruiting
Research Site
Hanover, Germany · Not yet recruiting
Research Site
München, Germany · Not yet recruiting
Research Site
Brescia, Italy · Not yet recruiting
Research Site
Rozzano, Italy · Not yet recruiting
Research Site
Torino, Italy · Not yet recruiting
Research Site
Verona, Italy · Withdrawn
Research Site
Lodz, Poland · Not yet recruiting
Research Site
Barcelona, Spain · Not yet recruiting
Research Site
Madrid, Spain · Not yet recruiting
Research Site
London, United Kingdom · Not yet recruiting
Research Site
Manchester, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.